The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2022 | RNAi therapy in patients with hATTR amyloidosis with cardiac and neurologic involvement
Marcus Anthony Urey, MD, University of California, San Diego, CA, comments on the use of RNA interference (RNAi) therapy in patients with hereditary transthyretin-mediated (hATTR) amyloidosis who have both cardiac and neurological involvement. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
Disclosures
Consultancy: Alnylam, Akcea, BridgeBio
Honoraria: Pfizer
Research support: Ionis
